MetaVia is trading 7.65% up now at $1.83 after preclinical results showed DA-1726 was broadly distributed, with the highest tissue exposure in adipose tissue.
- September 9, 2026, findings provided biological rationale for waist-circumference reduction and supported the drug’s differentiated profile.
- Prolonged tissue retention was consistent with once-weekly dosing.
- The study was mechanistic rather than clinical efficacy evidence.